September 22, 2018
At Late Breaking Trials of TCT 2018, Leaders Free in USA + Canada was successfully presented!
BioFreedom keeps showing superior Safety and Efficacy against BMS in HBR patients.
Results are comparable to Leader Free I.
• Patients in Leaders Free presented worst baseline characteristcs: They are younger and higher Body Mass Index than European patients.
• In this set of worst patients BioFreedom has outstanding results.
• High adoption of Radial Access and more than 98% of Device Success – Strut Thickness again is not a problem to cross the lesion or implant the stent (slide attached).